Pharmaceutical drug classification
ATC code C: Cardiovascular system |
---|
|
Other ATC codes |
ATC code C Cardiovascular system is a section of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3][4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QC.[5]
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
References
[edit]- ^ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
- ^ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
- ^ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
- ^ "ATC/DDD Index 2022: code C". WHO Collaborating Centre for Drug Statistics Methodology.
- ^ "ATCvet Index 2022: code QC". WHO Collaborating Centre for Drug Statistics Methodology.
Major chemical drug groups – based upon the Anatomical Therapeutic Chemical Classification System | |
---|---|
gastrointestinal tract / metabolism (A) | |
blood and blood forming organs (B) | |
cardiovascular system (C) | |
skin (D) | |
genitourinary system (G) | |
endocrine system (H) | |
infections and infestations (J, P, QI) | |
malignant disease (L01–L02) | |
immune disease (L03–L04) | |
muscles, bones, and joints (M) | |
brain and nervous system (N) |
|
respiratory system (R) | |
sensory organs (S) | |
other ATC (V) | |
Bufadienolides |
| ||||||
---|---|---|---|---|---|---|---|
Cardenolides |
| ||||||
|
Channel blockers |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Receptor agonists and antagonists |
| ||||||||||||
Ion transporters |
| ||||||||||||
|
Cardiac stimulants excluding cardiac glycosides (C01C) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adrenergic and dopaminergic agents |
| ||||||||||||||
Phosphodiesterase inhibitors (PDE3I) | |||||||||||||||
Other cardiac stimulants | |||||||||||||||
|
Nitrovasodilators | |
---|---|
Quinolone vasodilators | |
Others | |
|
Sympatholytics (antagonize α-adrenergic vasoconstriction) | |||||
---|---|---|---|---|---|
Other antagonists |
| ||||
|
Nitrovasodilator (arterioles and venules) | |
---|---|
Hydrazinophthalazines (arterioles) | |
Potassium channel openers (arterioles) | |
Calcium channel blockers (arterioles) |
|
|
Sulfonamides (and etacrynic acid) |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Potassium-sparing (at CD) |
| ||||||||
Osmotic diuretics (PT, DL) | |||||||||
Vasopressin receptor inhibitors (DCT and CD) | |||||||||
Other | |||||||||
Combination products | |||||||||
|
Phenylethanolamine derivatives | |
---|---|
Alpha blockers |
|
Niacin and derivatives | |
Purine derivatives | |
Ergot alkaloids | |
Other peripheral vasodilators |
Antihemorrhoidals for topical use |
| ||||||
---|---|---|---|---|---|---|---|
Antivaricose therapy |
| ||||||
Capillary stabilising agents |
|
β, non-selective | |
---|---|
β1-selective | |
β2-selective | |
α1- + β-selective | |
|
Calcium |
| ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Potassium |
| ||||||||||||||||||||||||
Sodium |
| ||||||||||||||||||||||||
Chloride |
| ||||||||||||||||||||||||
Others |
| ||||||||||||||||||||||||
ACE inhibitors ("-pril") |
|
---|---|
AIIRAs ("-sartan") | |
Renin inhibitors ("-kiren") | |
Dual ACE/NEP inhibitors | |
Neprilysin inhibitors | |
|
GI tract |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liver |
| ||||||||||||
Blood vessels |
| ||||||||||||
Combinations | |||||||||||||
Other | |||||||||||||
|